Central nervous system involvement in intravascular large B-cell lymphoma: A retrospective analysis of 109 patients

Cancer Science

Volumn 101, Issue 6, 2010, Pages 1480-1486

  Shimada, Kazuyuki ^a   Murase, Takuhei ^b   Matsue, Kosei ^c   Okamoto, Masataka ^d   Ichikawa, Naoaki ^e   Tsukamoto, Norifumi ^f   Niitsu, Nozomi ^g   Miwa, Hiroshi ^h   Asaoku, Hideki ⁱ   Kosugi, Hiroshi ^j   Kikuchi, Ako ^k   Matsumoto, Morio ^l   Saburi, Yoshio ^m   Masaki, Yasufumi ⁿ   Yamamoto, Kazuhito ^o   Yamaguchi, Motoko ^p   Nakamura, Shigeo ^q   Naoe, Tomoki ^a   Kinoshita, Tomohiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Nishio Municipal Hospital   (Japan)

^c Kameda General Hospital   (Japan)

^d FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NAGANO RED CROSS HOSPITAL   (Japan)

^f GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^h AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^j OGAKI MUNICIPAL HOSPITAL   (Japan)

^k TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l National Hospital Organization   (Japan)

^m OITA PREFECTURAL HOSPITAL   (Japan)

ⁿ KANAZAWA MEDICAL UNIVERSITY   (Japan)

^o AICHI CANCER CENTER HOSPITAL   (Japan)

^p MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q NAGOYA UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; METHOTREXATE; PREDNISOLONE; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVOR; CENTRAL NERVOUS SYSTEM TUMOR; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES;

EID: 77954170597     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01555.x     Document Type: Article

References (31)

1. Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC. CNS involvement in the non-Hodgkin's lymphomas. Cancer 1980, 45:545-52.
2. MacKintosh FR, Colby TV, Podolsky WJ. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 1982, 49:586-95.
3. van Besien K, Ha CS, Murphy S. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998, 91:1178-84.
4. Boehme V, Zeynalova S, Kloess M. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007, 18:149-57.
5. Doolittle ND, Abrey LE, Shenkier TN. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 2008, 111:1085-93.
6. Buckstein R, Lim W, Franssen E, Imrie KL. CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leuk Lymphoma 2003, 44:955-62.
7. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002, 13:1099-107.
8. Sariban E, Edwards B, Janus C, Magrath I. Central nervous system involvement in American Burkitt's lymphoma. J Clin Oncol 1983, 1:677-81.
9. Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol 1986, 4:847-58.
10. Haioun C, Besson C, Lepage E. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000, 11:685-90.
11. Nakamura S, Ponzoni M, Campo E. Intravascular large B-cell lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 252-3. Swerdlow SH, Campo E, Harris NLJaffe ESPileri SAStein HThiele JVardiman JW. eds, Lyon, France, IARC Press
12. Ponzoni M, Ferreri AJ, Campo E. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol 2007, 25:3168-73.
13. Murase T, Nakamura S, Kawauchi K. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 2000, 111:826-34.
14. Ferreri AJ, Campo E, Seymour JF. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol 2004, 127:173-83.
15. Imai H, Kajimoto K, Taniwaki M. Intravascular large B-cell lymphoma presenting with mass lesions in the central nervous system: a report of five cases. Pathol Int 2004, 54:231-6.
16. Beristain X, Azzarelli B. The neurological masquerade of intravascular lymphomatosis. Arch Neurol 2002, 59:439-43.
17. Viali S, Hutchinson DO, Hawkins TE. Presentation of intravascular lymphomatosis as lumbosacral polyradiculopathy. Muscle Nerve 2000, 23:1295-300.
18. Murase T, Yamaguchi M, Suzuki R. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007, 109:478-85.
19. Anghel G, Petrinato G, Severino A. Intravascular B-cell lymphoma: report of two cases with different clinical presentation but rapid central nervous system involvement. Leuk Lymphoma 2003, 44:1353-9.
20. Ohno T, Sakamoto T, Mizumoto C. Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy. Int J Hematol 2006, 84:74-8.
21. Shimada K, Matsue K, Yamamoto K. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008, 26:3189-95.
22. Ferreri AJ, Dognini GP, Govi S. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol 2008, 26:5134-6. author reply 6-7
23. Feugier P, Virion JM, Tilly H. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004, 15:129-33.
24. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009, 113:3896-902.
25. Gatter KC, Warnke RA. Intravascular large B-cell lymphoma. World Health Organization: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues 2001, 177-8. Jaffe ES, Harris NLStein HVardiman JW. eds, Lyon, France, IARC Press
26. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-94.
27. Ferreri AJ, Dognini GP, Campo E. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica 2007, 92:486-92.
28. Asada N, Odawara J, Kimura S. Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Mayo Clin Proc 2007, 82:1525-7.
29. Matsue K, Asada N, Takeuchi M. A clinicopathological study of 13 cases of intravascular lymphoma: experience in a single institution over a 9-yr period. Eur J Haematol 2008, 80:236-44.
30. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma. Cancer 2002, 95:576-80.
31. Arkenau HT, Chong G, Cunningham D. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 2007, 18:541-5.